Sharmayne R. E. Brady, Aya Mousa, Negar Naderpoor, Maximilian P. J. de Courten, Flavia Cicuttini, Barbora de Courten
Abstract
Objective:
To compare cardiometabolic risk factors including cytokine and adipokine concentrations between individuals with and without back pain.Methods:In 62 overweight/obese adults (BMI ≥ 25 kg/m2; 23F/39M), we collected data on: self-reported back pain; anthropometry [BMI, waist circumference, body composition (dual energy X-ray absorptiometry-DEXA)]; metabolic parameters [fasting glucose; insulin sensitivity (hyperinsulinaemic-euglycaemic clamps)]; cardiovascular parameters (blood pressure, lipids); serum inflammation markers [high-sensitivity C-reactive protein (hsCRP; immunoturbidimetric-assay), tumor necrosis factor-alpha(TNF-α), interleukin (IL)-6, and IL-10 (multiplex-assay)]; and adipokines [leptin, adipsin, resistin, and adiponectin (multiplex-assay)].Results:Participants who reported having back pain in the past month (n= 24; 39%) had higher BMI (mean ±SD= 33.8 ± 6.3 vs. 30.2 ± 4.1 kg/m2,p= 0.008), fat-mass (39.9 ± 12.3 vs. 33.9 ± 9.8%,p= 0.04), and waist circumference (109.6 ± 16.8 vs. 101.0 ± 9.3 cm,p= 0.01) compared to those without back pain (n= 38; 61%). No differences were observed in cardiometabolic parameters, inflammatory markers, or adiponectin or resistin concentrations. Those reporting back pain had higher adipsin concentrations compared to those without back pain [median (IQR) = 744 (472-2,804) vs. 721 (515-867) ng/ml,p= 0.03], with a trend for higher leptin [5.5 (1.5-24.3) vs. 2.3 (1.5-6.7) ng/ml,p= 0.05], both of which persisted after adjustment for age and sex. Adipsin remained associated with back pain independently of adiposity (BMI, waist, fat-mass, or total %body fat; allp≤ 0.03).Conclusions:Greater obesity, and higher adipsin and leptin concentrations were observed in those who reported back pain in the past month compared to those without back pain, and adipsin was associated with back pain independently of adiposity. Larger studies are needed to determine if adipsin could be a novel therapeutic target for prevention and/or treatment of back pain.
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2018.
All research outputs
#18,159,399
of 23,327,904 outputs
Outputs from Frontiers in Physiology
#7,388
of 14,058 outputs
Outputs of similar age
#315,723
of 446,865 outputs
Outputs of similar age from Frontiers in Physiology
#197
of 334 outputs
Altmetric has tracked 23,327,904 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,058 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,865 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 334 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
